METHODS:
We performed an open-label, single-center study of 57 patients with severe AH admitted to a Liver Intensive Care unit in India from October 2014 through March 2017. Patients were randomly assigned to groups that received standard medical therapy (with pentoxifylline) plus G-CSF for 5 days (G-CSF group; n [ 18), standard medical therapy plus G-CSF and intravenous NAC for 5 days (combination group; n [ 19) , or standard medical therapy alone (n [ 20) . Clinical data and blood samples were collected at baseline; on day 6; and 1, 2, and 3 months after the study began. CD34D cells were measured in blood samples collected on days 0 and 6. The primary outcome was proportion of patients surviving for 90 days. Secondary outcomes were mobilization of CD34D cells at day 6, as well as Child Turcotte Pugh, model for end-stage liver disease, and modified discriminant function scores until day 90.
RESULTS:
Significantly higher proportions of patients in the G-CSF group (16/18) and the combination group (13/19) survived for 90 days than in the standard medical therapy group (6/20) (P [ .0001 for G-CSF group and P [ .037 and combination group). The GGSF and combination groups each had increased numbers of CD34D cells from baseline until day 6, compared with the standard medical therapy group. The G-CSF group (but not the combination group) had significantly larger median reductions in modified discriminant function scores at study months 1 (reduction of 60.36%), 2 (reduction of 75.36%), and 3 (reduction of 88.73%) vs the standard medical therapy group (P [ .02; P [ .05; and P [ .00, respectively). The G-CSF group had a significantly larger median reduction in model for endstage liver disease score at 3 months (reduction of 55.77%; P ¼ .01), but not in Child Turcotte Pugh score, compared with the standard medical therapy group. All groups had similar numbers of complications.
S
evere alcoholic hepatitis (AH) carries a very high short-term mortality. 1 Traditional approaches including pentoxifylline and glucocorticoids are marginally effective in improving survival at 1 month and ineffective in improving 3-and 6-month survival [2] [3] [4] ; hence, there is an unmet need for newer therapies. Previously, it has been shown that in response to acute or chronic liver injury, bone marrow-derived stem cells can spontaneously populate liver and differentiate into hepatocytes. 5, 6 Both animal and human studies suggest that bone marrow-derived circulating pluripotent cells might contribute to hepatic regeneration and repair after various forms of acute liver injury. 7, 8 Recently, granulocyte colonystimulating factor (G-CSF) has been shown to be safe and efficacious in promoting the mobilization of bone marrow stem cells, [9] [10] [11] leading to improved histology and survival after liver injury. [8] [9] [10] [11] Also, the use of G-CSF in patients with acute-on-chronic liver failure (ACLF) and AH has been associated with clinical, biochemical, and histological improvement. [11] [12] [13] Another agent that could have a potential therapeutic role in the treatment of AH is N-acetylcysteine (NAC).
14 Whether a combination of NAC and G-CSF is better than G-CSF alone remains unknown. We hypothesized that a combination of G-CSF and NAC would have better outcomes compared with G-CSF alone. In this study, we evaluate the efficacy and safety of G-CSF and NAC in the treatment of patients with severe AH. We used pentoxifylline as the standard of care, as the trial protocol was finalized before publication of recent data.
Methods
The study protocol was approved by the Institutional Ethics Committee and the study conformed to the Helsinki declaration of 1977. A written informed consent was obtained from all subjects. All authors had access to the study data and reviewed and approved the final manuscript.
Patients
This was a prospective, open-label, single-center, pilot randomized study conducted in this Institute between October 2014 and March 2017.
Inclusion criteria. Patients with severe AH admitted to the Liver Intensive Care Unit were eligible for inclusion in the study if they fulfilled the following criteria: (1) 18-75 years of age; (2) diagnosis of AH 15 based on the following criteria: (a) history of heavy alcohol use (mean intake, approximately 100 g/day) during the 3 months before enrollment; (b) total serum bilirubin level >5 mg/dL (86 mmol/L), (c) aspartate aminotransferase: alanine aminotransferase ratio >2 and with an aspartate aminotransferase <300 U/L, (d) elevated prothrombin time (international normalized ratio), (e) leukocytosis; and (3) modified Maddrey's discriminant function (mDF), calculated as 4.6 Â patient's prothrombin timecontrol prothrombin time (in seconds) plus serum bilirubin level (mg/dL) of !32.
Exclusion criteria. Patients with any of the following were excluded: (1) hepatocellular carcinoma or portal vein thrombosis; (2) refusal to participate in the study; (3) prior treatment with glucocorticoids; (4) significant medical comorbid conditions including hepatorenal syndrome (serum creatinine >1.5 mg/dL), grade 3 or 4 hepatic encephalopathy, upper gastrointestinal bleeding within the preceding 10 days, uncontrolled bacterial infection, human immunodeficiency virus, hepatitis B virus, hepatitis C virus seropositivity, autoimmune hepatitis, hemochromatosis, Wilson's disease, and alpha 1-antitrypsin deficiency; (5) pregnancy; and (6) any previous known hypersensitivity to G-CSF and NAC.
Methods
The design of the study is illustrated in Supplementary Figure 1 . After obtaining informed, written consent and confirming inclusion and exclusion criteria, patients were randomized to 1 of the 3 treatment groups. The randomization was computer generated and the randomization sequence was placed in opaque sequentially numbered envelopes. Patients were treated with standard medical therapy (SMT) plus G-CSF (G-CSF group), SMT plus G-CSF and NAC (combination group), or SMT alone (SMT arm).
Treatment. G-CSF (Biocon, Bangalore, India) was given at a dose of 5mg/kg subcutaneously every 12 hours for 5 consecutive days. NAC (Cipla Limited, Mumbai, India) was administered intravenously (day 1: NAC at 150, 50, and 100 mg/kg in 250, 500, and 1000 mL of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2-5: 100 mg/kg/day in 1000 mL of 5% glucose solution).
14 The SMT arm involved treatment with pentoxifylline (Sanofi Pharma, Mumbai, India) at a dose of 400 mg 3 times a day for 28 days and normal hospital nutrition (1800-2000 kcal/day). Diuretics, sodium restriction and albumin for the treatment of ascites, fresh frozen plasma for coagulopathy, and antibiotics for any focus of infection such as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection were administered as indicated. All patients were admitted for at least 6 days following randomization, and longer, if necessary and were abstinent from alcohol throughout the study.
Monitoring. During the initial inpatient hospitalization patients were assessed daily for clinical status and adverse events. At baseline, day 6 and at 1, 2, and 3 months clinical information and laboratory data were collected to assess clinical status and to calculate the Child-Turcotte-Pugh (CTP), mDF, and the Model for EndStage Liver Disease (MELD) scores as indicators of liver failure and prognosis. We calculated the change in CTP, MELD, and mDF score as the D%, which was calculated as follows: (score at follow-up day minus score at baseline) / (score at baseline) x 100. Circulating CD34þ cells were measured on day 0 and day 6 of G-CSF therapy. The presence of systemic inflammatory response syndrome was made using the recommendations of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. 16 In addition, ultrasound examination was performed at days 1 and 6 to evaluate changes in spleen diameter. All patients were followed for a period of 3 months at monthly intervals.
Estimation of hematopoietic stem cells in peripheral blood. CD 34þ cells, which represent hematopoietic stem cells were measured, as previously described (Supplementary Appendix 1). 17 Study outcomes. The secondary endpoints included: (1) number of CD34þ cells in the peripheral blood at day 6; (2) improvement in the clinical scores (MELD, mDF, CTP) at day 6 and 1, 2 and 3 months; and (3) adverse effects of G-CSF and NAC. We compared the outcomes in G-CSF and combination groups with reference to standard of care; and, we also compared the outcomes in the combination group compared to G-CSF alone. The primary endpoint was survival at 90 days after inclusion in the study.
Statistical Analysis
Statistical analysis was carried out using SPSS version 22.0 for Microsoft Windows (IBM Corp, Armonk, NY). Data are presented as mean AE SD or median (range). Normality of data was checked by the Kolmogorov-Smirnov test. For normally distributed data, means were compared using Student's t test for 2 groups. For nonparametric data, the Mann-Whitney U test was applied. Qualitative or categorical variables were described as frequencies and proportions. The protocol proposed 2 statistical comparisons. First, to compare 90-day survival in the standard of care arm with survival among subjects receiving G-CSF alone and the G-CSF plus NAC. Second, to compare 90-day survival between the G-CSF arm and the combination treatment arm (G-CSF plus NAC).
Proportions were compared using chi-square or Fisher's exact test, as applicable. To determine the relationship between different quantitative variables, the Pearson or Spearman correlation coefficient were applied. For time-related variables, Wilcoxon signed rank test or repeated measures analysis of variance was applied. Kaplan-Meier survival curves were plotted for up to 90 days and compared with the use of a log-rank test. All statistical tests were 2 sided and were performed at a significance level of a ¼ 0.05. As we conducted a pilot study, no power calculation was performed.
Results
Ninety-two consecutive patients with severe AH were screened (Supplementary Figure 1) , and 57 patients were finally included in the study. Eighteen patients received SMT plus G-CSF, 19 received SMT plus G-CSF plus NAC, and 20 received SMT alone. Thirty-five patients were excluded from the study for the following reasons: evidence of sepsis (n ¼ 15), renal failure (n ¼ 5), pneumonia with sepsis and renal failure (n ¼ 6), hepatitis C virus infection (n ¼ 1), gastrointestinal bleeding (n ¼ 2), grade 4 hepatic encephalopathy (n ¼ 1), and refusal to participate (n ¼ 5). The baseline characteristics of the study population were similar in the 3 groups (Table 1 ).
Primary outcome. Two patients in the G-CSF group, 6 in the combination group, and 14 in the SMT group had died at 90-day follow-up (P < .001) (Figure 1 ). There was better 90-day survival in the G-CSF group and combination group compared with the SMT group (P < .05). However, there was no significant difference in 90-day survival between the combination and G-CSF groups (P ¼ .112). In the G-CSF group, the deaths were due to upper gastrointestinal bleed with pneumonia, hepatorenal syndrome (HRS) and sepsis (n ¼ 1), and pneumonia, SBP, sepsis, renal failure, and multiple organ dysfunction syndrome (n ¼ 1). In the combination group, the deaths were due to upper gastrointestinal bleed with pneumonia, HRS, and sepsis (n ¼ 2), and pneumonia, SBP, sepsis, renal failure, and multiple organ dysfunction syndrome (n ¼ 4). In SMT group, the deaths were due to upper gastrointestinal bleed with pneumonia, HRS, and sepsis (n ¼ 2); pneumonia, SBP, sepsis, renal failure, and multiple organ dysfunction syndrome (n ¼ 4); and severe sepsis with septic shock (n ¼ 8). There were no other infections other than the ones listed, which resulted in death.
Neutrophils and CD34D Cells. Baseline total leukocyte and CD34þ cells were similar in all the groups (Table 1) . There was a significant increase in total leukocyte count and CD34þ cells in the peripheral blood on day 6 in the G-CSF and combination therapy groups, as compared with baseline and SMT groups ( Table 2 ).There was no significant increase in total leukocyte count and CD34þ cells on day 6 in the SMT group as compared with baseline (Table 2) .
Renal function and serum electrolytes. Baseline renal function and electrolytes were comparable in all the groups (Table 1 ). There was a significant increase in serum sodium on day 6 in G-CSF group as compared with day 0 (Table 2) . There was no change in serum creatinine on day 6 in G-CSF and combination groups and there was an increase in SMT group (Table 2) .
Liver function and clinical severity scores. Baseline liver function parameters were comparable in all the groups (Table 1 ). There was a significant increase in serum alkaline phosphatase and albumin, and reduction in bilirubin and international normalized ratio on day 6 in G-CSF group as compared with day 0 (Table 2) . There was a significant increase in alkaline phosphatase on day 6 compared with day 0 in the combination group (Table 2) . There was significant increase in alkaline phosphatase on day 6 in G-CSF and combination groups as compared with the SMT group ( Table 2) . At baseline, the CTP, MELD, and mDF scores were comparable in all the groups (Table 1) . There was significant improvement in the clinical severity scores on day 6 compared with day 0 in G-CSF group but not in the combination and the SMT group (Table 2) .There was significant decrease in CTP score on day 6 in the granulocyte colony-stimulating factor group as compared with the combination group and in CTP and MELD scores as compared with the SMT arm ( Table 2 ). There was a significant reduction in median D% in mDF at 1, 2, and 3 months and MELD at 3 months in G-CSF group as compared with SMT (P < .05) ( Table 3 ). However, there was no significant reduction in median D% in CTP, mDF and MELD at 1, 2, and 3 months in the combination group as compared with the SMT group (Table 3) .
Adverse events. G-CSF and combination therapy was well tolerated in all patients. There were minor adverse events and no patient required withdrawal of therapy (Supplementary Appendix 2).
Discussion
The results of this pilot study suggest that treatment with G-CSF may lead to a better 90-day survival compared with SMT alone. Importantly, the combination Figure 1 . Kaplan-Meier curve showing the cumulative probability of survival at day 90 of patients treated with granulocyte colony-stimulating factor (G-CSF), combination, and standard medical therapy (control). The difference between the 3 groups was statistically significant (P < .001, log-rank test). There was better 90-day survival in the G-CSF group and combination group compared with SMT (P ¼ .0001 and .037, respectively). However, there was no significant difference in 90-day survival between the combination and G-CSF groups (P ¼ .112). NAC, N-acetylcysteine. of NAC and G-CSF was not found to be superior to G-CSF alone in improving 90-day mortality. Several studies have demonstrated the efficacy of G-CSF in mobilizing stem cells from bone marrow to liver, [8] [9] [10] [11] with resultant improvement in clinical, biochemical, and histological profile in patients with advanced liver disease. [11] [12] [13] In 1 study evaluating the short term effects of G-CSF, the authors found that G-CSF mobilized CD34þ cells, increased levels of hepatocyte growth factor, and induced hepatic progenitor cells to proliferate within 7 days of administration. 12 However, the study did not demonstrate any improvement in liver function, as it was not powered to detect clinical improvement. In another study conducted in patients with severe AH, the use of G-CSF led to mobilization of hematopoietic stem cells and improved liver function as well as survival.
11 Even in the current study, there was a significant reduction in median D% in mDF at 1, 2, and 3 months and MELD at 3 months in patients treated with G-CSF as compared with controls.
There was a poor 90-day survival in the SMT group despite pentoxifylline therapy in these patients. Pentoxifylline therapy has been shown to have good short-term survival in severe AH in a previous study, 3 but no effect in recent studies. 2, 4 We had chosen pentoxifylline as standard therapy, as the study protocol was finalized before the publication of recent trials. Whether pentoxifylline should be the reference standard in future studies remains debatable. In the present study, there was high mortality in the SMT arm similar to previous studies, 11, 13 probably because of the late referral to the hospital and not due to pentoxifylline per se, as it was administered to all the 3 groups. In fact, the baseline mDF in the present study was much higher (median 77.4) compared with a previous (mean 45.9) study. 3 NAC therapy has been shown to be beneficial in mouse models of acute and chronic AH. 18, 19 In 2 randomized trials of patients with severe AH, the benefits of antioxidants were not evident. 20, 21 However, a recent trial found improvement in short-term (1-month mortality: 8% vs 24%, P ¼ .006) but not midterm (3 and 6 months) outcomes. 14 The addition of NAC to prednisolone was associated with a reduced rate of infection.
14 In the present study, outcomes in the combination therapy arm were not superior to G-CSF group alone. The apparent lack of benefit could either be due to the small sample size or it is possible that 5-day duration of NAC therapy is insufficient. A longer period of intravenous NAC combined with G-CSF with subsequent oral administration of NAC until 1 month may be considered in future trials. In the present study, sepsis was the cause of mortality in majority of patients in the SMT group. However, the addition of NAC to G-CSF was not found to offer additional benefits.
What are the clinical implications of our study? The current study found a significant improvement in liver function as well as survival in patients with severe AH after G-CSF, as also previously shown. 11 Further, G-CSF therapy was safe and there were no major side effects of G-CSF therapy similar to previous experience. 9, 10, 12, 13 If our study results are replicated in other centers, G-CSF may become the first-line treatment in the management of severe AH.
Finally, our study has a few limitations. It is possible that the diagnosis of AH might have been incorrect in a small number of the patients in our study as we did not perform liver biopsy; however, when strict clinical criteria are used, it is possible to diagnose the condition with a high degree of accuracy. 22 The use of liver biopsy to provide histologic confirmation of alcoholic steatohepatitis before considering glucocorticoid treatment is a contentious issue. 23 Although many investigators have used histologic confirmation as an entry criterion, liver biopsy is rarely performed in clinical practice except in those cases where the diagnosis remains uncertain. 23 Finally, the current study was an open-label, single-center pilot study.
In conclusion, G-CSF therapy with or without NAC is safe and effective in mobilization of hematopoietic stem cells with potential to improve liver function and survival at 3 months in patients with severe AH compared with SMT alone. The use of NAC probably does not have any additional benefit compared with G-CSF. Due to the small sample size, the results will need to be confirmed in larger studies before clinical implementation.
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